X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The Company intends to use the net proceeds from the private placement to fund the SZN-043 clinical development program, including the expansion of the SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis.
Lead Product(s): SZN-043
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: SZN-043
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: RA Capital Management
Deal Size: $192.5 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 01, 2024
Details:
SZN-043 is a hepatocyte-targeted R-spondin mimetic, monoclonal antibody. It is being evaluated for the treatment of severe liver diseases, initially focusing on alcohol-associated hepatitis.
Lead Product(s): SZN-043
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: SZN-043
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2024
Details:
SZN-043, an R-Spondin mimetic by enhancing Wnt signaling in a cell-targeted manner, in preclinical data it showed rapid, transient increases in hepatocyte proliferation and was well tolerated in non-clinical toxicology studies.
Lead Product(s): SZN-043
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: SZN-043
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2022
Details:
Under the terms of the agreement, Boehringer Ingelheim will receive an exclusive, worldwide license to develop SZN-413 and other Fzd4-specific Wnt-modulating molecules for all purposes, including as a treatment for retinal diseases.
Lead Product(s): SZN-413
Therapeutic Area: Ophthalmology Product Name: SZN-413
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: $599.0 million Upfront Cash: $12.5 million
Deal Type: Collaboration October 06, 2022
Details:
SZN-413, a bi-specific antibody that targets FZD4 and LRP5, induced Wnt signaling and upregulated blood-retinal barrier gene expression in retinal ECs. SZN-413 reduced the pathologic neovascularization area size compared to vehicle and comparable to the positive control.
Lead Product(s): SZN-413
Therapeutic Area: Ophthalmology Product Name: SZN-413
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2022
Details:
In preclinical models of liver injury and fibrosis, SZN-043 has been shown to selectively activate Wnt signaling, stimulate transient hepatocyte proliferation, improve liver function and reduce fibrosis with no treatment-related adverse effects observed in GLP toxicology.
Lead Product(s): SZN-043
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: SZN-043
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 13, 2022
Details:
The data demonstrate that in an acute dextran sodium sulfate (DSS) epithelial damage model, SZN-1326 promoted mucosal healing by transiently inducing epithelial progenitor cell expansion and accelerating epithelial repair.
Lead Product(s): SZN-1326
Therapeutic Area: Gastroenterology Product Name: SZN-1326
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2022
Details:
SZN-1326 is the first development candidate designed using Surrozen’s SWAP™ technology and targets the Wnt-signaling pathway in the intestinal epithelium. In preclinical animal models of acute and chronic colitis.
Lead Product(s): SZN-1326
Therapeutic Area: Gastroenterology Product Name: SZN-1326
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2022
Details:
Preclinical data suggest that SZN-413 can simultaneously address retinal non-perfusion and leakage in blood vessels in retinal vascular diseases for the treatment of diabetic retinopathy.
Lead Product(s): SZN-413
Therapeutic Area: Ophthalmology Product Name: SZN-413
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2022
Details:
SZN-043 binds to the ASGR receptor and increases ALP serum concentration by interfering with ALP elimination occurring through the ASGR receptor. The Preclinical studies of SZN-043 showing improved liver metabolic function.
Lead Product(s): SZN-043
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: SZN-043
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
